Established the principle of “collateral lethality” and identified ENO2 as a target for therapeutic intervention by demonstrating that ENO2-depleation selectively inhibited growth, survival and the tumorigenic potential of ENO1-deleted GBM cells.
Source: Passenger deletions generate therapeutic vulnerabilities in cancer
